Donor Hemovigilance

AABB's donor hemovigilance efforts focus primarily on education, collaboration with other international organizations, and projects undertaken by the AABB Donor Hemovigilance Working Group.

Current Study

A sub-group of the AABB Donor Hemovigilance Working Group conducted a multi-center study to describe the demographics of returning COVID-19 convalescent plasma (CCP) and standard blood product first-time donors during the pandemic.

Please check the resource section to access the publication.

COVID-19 Convalescent Plasma Donor Hemovigilance Study

A sub-group of the AABB Donor Hemovigilance Working Group conducted a multi-center study in 2020 to evaluate the safety of CCP donation and determine whether CCP donors are at increased risk of donor adverse events (DAE) compared with conventional plasma donors.

Please check the resource section to access the publication.

Severity Grading Tool for Donor Adverse Events

The Severity Grading Tool for Donor Adverse Events was developed and validated by a sub-group of the AABB Donor Hemovigilance Working Group. Results of the formal validation study have been published (Transfusion, 2020).

The Severity Grading Tool for Donor Adverse Events was developed to enhance objective assignment of DAE severity. The tool is designed to be used with the Standard for Surveillance of Complications Related to Blood Donation by ISBT/AABB/IHN. The tool aims to avoid terms such as mild, moderate and severe. It is patterned after an established clinical severity scale, Common Terminology Criteria for Adverse Events (CTCAE1) v 5.0, which rates severity by Grades 1-5 with 1 through 5 being roughly associated with mild, moderate, severe, life-threatening and death; reactions of Grade 3 or higher would be classed as "serious" in donor adverse event reporting systems.

Resources

• Standard for Surveillance of Complications Related to Blood Donation (SSCRBD) (PDF)
• SSCRBD Pocket Reference Card (PDF)
• Severity Grading Tool for Donor Adverse Events (PDF)
• Van Buren NL, Rajbhandary S, Reynolds V, Gorlin JB, Stramer SL, Notari EP IV, et al. Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors. Transfusion. 2023;63(3):552–63. https://doi.org/10.1111/trf.17229
• Cho, JH, Rajbhandary, S, van Buren, NL, et al. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study. Transfusion. 2021; 1– 9. https://doi.org/10.1111/trf.16572
• Townsend M, Kamel H, Van Buren N, et al. Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events. Transfusion 2020 (https://doi.org/10.1111/trf.15830)

AABB Donor Hemovigilance Reports

• AABB Donor Hemovigilance Report 2012 (PDF)
• 2012-2014 AABB Donor Hemovigilance Report (PDF)
• 2012-2017 AABB Donor Hemovigilance Highlights (PDF)
  

Questions? Contact Hemovigilance@aabb.org or +1.301.215.6588.